Wellgistics Health, Inc. Common Stock(WGRX)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES (5122)
- Exchange
- XNAS
- Market Cap
- $0.0B
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -10.35% | 1 |
| Feb | -36.51% | 2 |
| Mar | -2.14% | 2 |
| Apr | +5.95% | 2 |
| May | -45.35% | 2 |
| Jun | -24.90% | 2 |
| Jul | -7.67% | 1 |
| Aug | +41.38% | 1 |
| Sep | -26.69% | 1 |
| Oct | -20.63% | 1 |
| Nov | -9.77% | 1 |
| Dec | -29.29% | 1 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 1.48
- Correlation (SPY)
- 6.8%
- R²
- 0.00
- Ann. Volatility
- 266.9%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-04-23 | Prashant Patel | Chief Executive Officer | Award (A) | +5,000,000 | $0.20 | $1.00M | EDGAR |
| 2026-04-23 | SURENDRA K AJJARAPU | Director | Award (A) | +5,000,000 | $0.20 | $1.00M | EDGAR |
| 2025-07-08 | MICHAEL L PETERSON | Director | Award (A) | −200,000 | $0.90 | -$180.0K | EDGAR |
| 2025-03-25 | Shafaat Pirani | Chief Clinical Officer | Award (A) | +35,000 | — | EDGAR | |
| 2025-03-25 | DONALD WILLIAM ANDERSON | Director | Award (A) | +200,000 | — | EDGAR | |
| 2025-03-25 | Nikul Panchal | Chief Pharmacy Officer | Award (A) | +90,000 | — | EDGAR | |
| 2025-03-25 | Sajid Syed | Director | Award (A) | +200,000 | — | EDGAR | |
| 2025-03-25 | SURENDRA K AJJARAPU | Director | Award (A) | +4,082,247 | — | EDGAR | |
| 2025-03-25 | REBECCA M SHANAHAN | Director | Award (A) | +200,000 | — | EDGAR | |
| 2025-03-25 | Prashant Patel | Chief Strategy Officer | Award (A) | +4,082,247 | — | EDGAR | |
| 2025-03-25 | Brian Norton | Chief Executive Officer | Award (A) | +9,000,000 | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | SURENDRA K AJJARAPU | Director | 12,345,447 | $42.96M | $0 | 2 | 2026-04-23 |
| 2 | Prashant Patel | Chief Executive Officer | 9,818,247 | $34.17M | $0 | 2 | 2026-04-23 |
| 3 | Brian Norton | Chief Executive Officer | 9,244,687 | $32.17M | $0 | 1 | 2025-03-25 |
| 4 | Nikul Panchal | Chief Pharmacy Officer | 375,761 | $1.31M | $0 | 1 | 2025-03-25 |
| 5 | REBECCA M SHANAHAN | Director | 244,720 | $851.6K | $0 | 1 | 2025-03-25 |
| 6 | DONALD WILLIAM ANDERSON | Director | 244,720 | $851.6K | $0 | 1 | 2025-03-25 |
| 7 | Sajid Syed | Director | 244,720 | $851.6K | $0 | 1 | 2025-03-25 |
| 8 | MICHAEL L PETERSON | Director | 200,000 | $696.0K | $0 | 1 | 2025-07-08 |
| 9 | Shafaat Pirani | Chief Clinical Officer | 102,080 | $355.2K | $0 | 1 | 2025-03-25 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.